Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18797530rdf:typepubmed:Citationlld:pubmed
pubmed-article:18797530lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:18797530lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:18797530lifeskim:mentionsumls-concept:C0004057lld:lifeskim
pubmed-article:18797530lifeskim:mentionsumls-concept:C0441471lld:lifeskim
pubmed-article:18797530lifeskim:mentionsumls-concept:C0070166lld:lifeskim
pubmed-article:18797530lifeskim:mentionsumls-concept:C0087086lld:lifeskim
pubmed-article:18797530lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:18797530pubmed:issue9lld:pubmed
pubmed-article:18797530pubmed:dateCreated2008-9-17lld:pubmed
pubmed-article:18797530pubmed:abstractTextClopidogrel and aspirin both inhibit platelet aggregation, but have differing mechanisms of action that are additive in terms of antithrombotic function. The additive antithrombotic effect of aspirin and clopidogrel combination therapy provides additional clinical benefit compared to monotherapy in some circumstances, but the risk of major bleeding with combination therapy is greater than with either agent alone.lld:pubmed
pubmed-article:18797530pubmed:languageenglld:pubmed
pubmed-article:18797530pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797530pubmed:citationSubsetIMlld:pubmed
pubmed-article:18797530pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797530pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797530pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797530pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797530pubmed:statusMEDLINElld:pubmed
pubmed-article:18797530pubmed:monthSeplld:pubmed
pubmed-article:18797530pubmed:issn0300-8495lld:pubmed
pubmed-article:18797530pubmed:authorpubmed-author:StocksNigelNlld:pubmed
pubmed-article:18797530pubmed:authorpubmed-author:RowettDebraDlld:pubmed
pubmed-article:18797530pubmed:authorpubmed-author:JackowskiLesl...lld:pubmed
pubmed-article:18797530pubmed:issnTypePrintlld:pubmed
pubmed-article:18797530pubmed:volume37lld:pubmed
pubmed-article:18797530pubmed:ownerNLMlld:pubmed
pubmed-article:18797530pubmed:authorsCompleteYlld:pubmed
pubmed-article:18797530pubmed:pagination721-3, 725-6lld:pubmed
pubmed-article:18797530pubmed:meshHeadingpubmed-meshheading:18797530...lld:pubmed
pubmed-article:18797530pubmed:meshHeadingpubmed-meshheading:18797530...lld:pubmed
pubmed-article:18797530pubmed:meshHeadingpubmed-meshheading:18797530...lld:pubmed
pubmed-article:18797530pubmed:meshHeadingpubmed-meshheading:18797530...lld:pubmed
pubmed-article:18797530pubmed:meshHeadingpubmed-meshheading:18797530...lld:pubmed
pubmed-article:18797530pubmed:meshHeadingpubmed-meshheading:18797530...lld:pubmed
pubmed-article:18797530pubmed:year2008lld:pubmed
pubmed-article:18797530pubmed:articleTitleReducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel.lld:pubmed
pubmed-article:18797530pubmed:affiliationSansom Institute, University of South Australia.lld:pubmed
pubmed-article:18797530pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18797530pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:18797530pubmed:publicationTypeReviewlld:pubmed